drugset / Trial / NCT06366412

Dexmedetomidine on Postoperative Cognitive Dysfunction and Serum Tau-217 Protein.

NCT06366412 ↗

Phase 4 Unknown 94 enrolled Minia University Hospital
RandomizedParallel-groupQuadruple-blindScreening

Summary

To assess the effect of Dexmedetomidine on serum Tau-217 protein and its relation to the incidence and severity of postoperative cognitive dysfunction in elderly patients undergoing major surgery under general anesthesia.

Timeline

Start
2024-04
Primary completion
2025-03
Completion
2026-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.3 ug/kg —

Indications